15 Jul 2021 Galapagos reports positive topline results with selective TYK2 inhibitor GLPG3667 in Phase 1b psoriasis study Member news
15 Jul 2021 Galapagos demonstrates early clinical activity with SIK2/3 inhibition in inflammation Member news
01 Jul 2021 Sequana Medical announces positive results from second interim analysis of North American pivotal alfapump® study (POSEIDON) Member news
14 Jun 2021 Precigen ActoBio announces positive topline results from Phase 1b/2a Study of AG019 ActoBiotics™ Member news
19 May 2021 Galapagos announces first patient enrolled in FILOSOPHY study to advance understanding of Jyseleca (filgotinib) effectiveness and safety in a real-world setting Member news
11 May 2021 Sequana Medical announces strong top-line results from RED DESERT alfapump DSR® study and expansion of DSR® development programme Member news
28 Apr 2021 Precirix partners with Evergreen to expand North American clinical trial supply Member news
More info? Ellen Telleir Communications Project Manager linkedin.com/in/ellentelleir/ ellen.telleir@biovia.be Contact us
